Cutting	O
edge	O
:	O
dominant	O
effect	O
of	O
Ile50Val	B-protein
variant	I-protein
of	O
the	O
human	B-protein
IL-4	I-protein
receptor	I-protein
alpha-chain	I-protein
in	O
IgE	B-protein
synthesis	O
.	O

Two	O
variants	O
of	O
the	O
IL-4R	B-DNA
alpha-chain	I-DNA
(	I-DNA
IL-4Ralpha	I-DNA
)	I-DNA
gene	I-DNA
have	O
been	O
recently	O
identified	O
in	O
association	O
with	O
different	O
atopic	O
disorders	O
.	O

To	O
clarify	O
the	O
etiological	O
relationship	O
between	O
the	O
two	O
variants	O
,	O
we	O
analyzed	O
responsiveness	O
to	O
IL-4	B-protein
of	O
transfectants	O
with	O
four	O
kinds	O
of	O
IL-4Ralpha	B-protein
carrying	O
either	O
Val	O
or	O
Ile	O
at	O
50	B-protein
and	O
either	O
Gln	O
or	O
Arg	O
at	O
551	B-protein
.	O

The	O
substitution	O
of	O
Ile	O
for	O
Val	O
augmented	O
STAT6	B-protein
activation	O
,	O
proliferation	O
,	O
and	O
transcription	O
activity	O
of	O
the	O
Iepsilon	B-DNA
promoter	I-DNA
by	O
IL-4	B-protein
,	O
whereas	O
that	O
of	O
Arg	O
for	O
Gln	O
did	O
not	O
change	O
these	O
IL-4	B-protein
signals	O
.	O

Arg551	O
was	O
not	O
associated	O
with	O
atopic	O
asthma	O
in	O
the	O
Japanese	O
population	O
.	O

CD23	B-protein
expression	O
and	O
IgE	B-protein
synthesis	O
by	O
IL-4	B-protein
were	O
augmented	O
in	O
Ile50-bearing	B-cell_line
PBMC	I-cell_line
,	O
compared	O
with	O
those	O
bearing	O
Val50	O
.	O

Taken	O
together	O
,	O
substitution	O
of	O
Arg551	O
does	O
not	O
enhance	O
the	O
IL-4	B-protein
signal	O
for	O
generation	O
of	O
germline	O
epsilon	O
transcript	O
,	O
whereas	O
the	O
substitution	O
of	O
Ile50	O
contributes	O
to	O
enhancement	O
of	O
IgE	B-protein
synthesis	O
.	O

K	NULL
Boldly	NULL
GolnVivo	NULL
``	NULL
``	NULL
BioLegend®	NULL
Le	NULL
meJournal	NULL
o	NULL
Cutting	NULL
Edge	NULL
:	NULL
Dominant	NULL
Effect	NULL
of	NULL
HeSOVal	NULL
P	NULL
'	NULL
Imnmunolo	NULL
gy	NULL
Variant	NULL
of	NULL
the	NULL
Human	NULL
IL-4	NULL
Receptor	NULL
«	NULL
-Chain	NULL
in	NULL
IgE	NULL
Synthesis	NULL
is	NULL
j	NULL
fon	NULL
i	NULL
Hiromichi	NULL
Mitsuyasu	NULL
,	NULL
Yukiyoshi	NULL
Yanagihara	NULL
,	NULL
Xiao-Quan	NULL
Z	NULL
?	NULL

ﬁégfggmggi	NULL
)	NULL
;	NULL
is	NULL
current	NULL
as	NULL
Mao	NULL
,	NULL
Pei-Sun	NULL
Gao	NULL
,	NULL
Yojiro	NULL
Arinobu	NULL
,	NULL
Kenji	NULL
Ihara	NULL
,	NULL
Akira	NULL
'	NULL
Takabayash1	NULL
,	NULL
Toshiro	NULL
Hara	NULL
,	NULL
Tadao	NULL
Enomoto	NULL
,	NULL
Sei	NULL
Sasaki	NULL
,	NULL
Minoru	NULL
Kawai	NULL
,	NULL
Naotaka	NULL
Hamasaki	NULL
,	NULL
Taro	NULL
Shirakawa	NULL
,	NULL
Julian	NULL
M.	NULL
Hopkin	NULL
and	NULL
Kenji	NULL
Izuhara	NULL
J	NULL
Immunol	NULL
1999	NULL
;	NULL
162:1227-1231	NULL
;	NULL
;	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/3/1227	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
25	NULL
articles	NULL
,	NULL
11	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.jimmunol.org/content/162/3/1227	NULL
.	NULL

full	NULL
#	NULL
ref-list-1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_-	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
(	NULL
CTIDG	NULL
€	NULL
=\	NULL
a	NULL
)	NULL
Cutting	NULL
Edge	NULL
:	NULL
Dominant	NULL
Effect	NULL
of	NULL
HeS0Val	NULL
Variant	NULL
of	NULL
the	NULL
Human	NULL
IL-4	NULL
Receptor	NULL
&	NULL
«	NULL
-Chain	NULL
in	NULL
IgE	NULL
Synthesis	NULL
!	NULL

Hiromichi	NULL
Mitsuyasu	NULL
,	NULL
*	NULL
Yukiyoshi	NULL
Yanagihara	NULL
,	NULL
``	NULL
Xiao-Quan	NULL
Mao	NULL
,	NULL
*	NULL
Pei-Sun	NULL
Gao	NULL
,	NULL
*	NULL
Yojiro	NULL
Arinobu	NULL
,	NULL
*	NULL
Kenji	NULL
Ihara	NULL
,	NULL
}	NULL
Akira	NULL
Takabayashi	NULL
,	NULL
§	NULL
Toshiro	NULL
Hara	NULL
,	NULL
}	NULL
Tadao	NULL
Enomoto	NULL
,	NULL
``	NULL
Sei	NULL
Sasaki	NULL
,	NULL
!	NULL

Minoru	NULL
Kawai	NULL
,	NULL
**	NULL
Naotaka	NULL
Hamasaki	NULL
,	NULL
*	NULL
Taro	NULL
Shirakawa	NULL
,	NULL
*	NULL
Julian	NULL
M.	NULL
Hopkin	NULL
,	NULL
*	NULL
and	NULL
Kenji	NULL
Izuhara*	NULL
Two	NULL
variants	NULL
of	NULL
the	NULL
IL-4R	NULL
«	NULL
-chain	NULL
(	NULL
IL-4Ra	NULL
)	NULL
gene	NULL
have	NULL
been	NULL
recently	NULL
identified	NULL
in	NULL
association	NULL
with	NULL
different	NULL
atopic	NULL
disorders	NULL
.	NULL

To	NULL
clarify	NULL
the	NULL
etiological	NULL
relationship	NULL
between	NULL
the	NULL
two	NULL
variants	NULL
,	NULL
we	NULL
analyzed	NULL
responsiveness	NULL
to	NULL
IL-4	NULL
of	NULL
transfectants	NULL
with	NULL
four	NULL
kinds	NULL
of	NULL
IL-4Ra	NULL
«	NULL
carrying	NULL
either	NULL
Val	NULL
or	NULL
He	NULL
at	NULL
50	NULL
and	NULL
either	NULL
Gln	NULL
or	NULL
Arg	NULL
at	NULL
551	NULL
.	NULL

The	NULL
substitution	NULL
of	NULL
He	NULL
for	NULL
Val	NULL
augmented	NULL
STAT6	NULL
activation	NULL
,	NULL
proliferation	NULL
,	NULL
and	NULL
transcription	NULL
activity	NULL
of	NULL
the	NULL
Ie	NULL
promoter	NULL
by	NULL
IL-4	NULL
,	NULL
whereas	NULL
that	NULL
of	NULL
Arg	NULL
for	NULL
Gin	NULL
did	NULL
not	NULL
change	NULL
these	NULL
IL-4	NULL
signals	NULL
.	NULL

Arg®	NULL
``	NULL
``	NULL
was	NULL
not	NULL
associated	NULL
with	NULL
atopic	NULL
asthma	NULL
in	NULL
the	NULL
Japanese	NULL
population	NULL
.	NULL

CD23	NULL
expression	NULL
and	NULL
IgE	NULL
synthesis	NULL
by	NULL
IL-4	NULL
were	NULL
augmented	NULL
in	NULL
He	NULL
``	NULL
-bearing	NULL
PBMC	NULL
,	NULL
compared	NULL
with	NULL
those	NULL
bearing	NULL
Val	NULL
``	NULL
°	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
substitution	NULL
of	NULL
Arg	NULL
``	NULL
does	NULL
not	NULL
enhance	NULL
the	NULL
IL-4	NULL
signal	NULL
for	NULL
generation	NULL
of	NULL
germline	NULL
e	NULL
transcript	NULL
,	NULL
whereas	NULL
the	NULL
substitution	NULL
of	NULL
He°	NULL
``	NULL
contributes	NULL
to	NULL
enhancement	NULL
of	NULL
IgE	NULL
synthesis	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
1999	NULL
,	NULL
162	NULL
:	NULL
1227-1231.	NULL
topy	NULL
,	NULL
an	NULL
immune	NULL
disorder	NULL
characterized	NULL
by	NULL
heightened	NULL
IgE	NULL
responsiveness	NULL
,	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
largely	NULL
regulated	NULL
by	NULL
genetic	NULL
factors	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

The	NULL
difficulty	NULL
of	NULL
identifying	NULL
atopy-causing	NULL
genes	NULL
can	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
existence	NULL
of	NULL
more	NULL
than	NULL
one	NULL
*Department	NULL
of	NULL
Clinical	NULL
Chemistry	NULL
and	NULL
Laboratory	NULL
Medicine	NULL
,	NULL
Faculty	NULL
of	NULL
Medicine	NULL
,	NULL
Kyushu	NULL
University	NULL
,	NULL
Fukuoka	NULL
,	NULL
Japan	NULL
;	NULL
*Clinical	NULL
Research	NULL
Center	NULL
for	NULL
Allergy	NULL
,	NULL
National	NULL
Sagamihara	NULL
Hospital	NULL
,	NULL
Sagamihara	NULL
,	NULL
Japan	NULL
;	NULL
*Department	NULL
of	NULL
Experimental	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Wales	NULL
,	NULL
Swansea	NULL
,	NULL
United	NULL
Kingdom	NULL
;	NULL
*Department	NULL
of	NULL
Pediatrics	NULL
,	NULL
Faculty	NULL
of	NULL
Medicine	NULL
,	NULL
Kyushu	NULL
University	NULL
,	NULL
Fukuoka	NULL
,	NULL
Japan	NULL
;	NULL
``	NULL
Department	NULL
of	NULL
Otolaryngology	NULL
,	NULL
Japanese	NULL
Red	NULL
Cross	NULL
Society	NULL
,	NULL
Wakayama	NULL
Medical	NULL
Center	NULL
,	NULL
Wakayama	NULL
,	NULL
Japan	NULL
;	NULL
HDepart—	NULL
ment	NULL
of	NULL
Pediatrics	NULL
,	NULL
Osaka	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Takatsuki	NULL
,	NULL
Japan	NULL
;	NULL
and	NULL
**Kyoto	NULL
Preventive	NULL
Medical	NULL
Center	NULL
,	NULL
Kyoto	NULL
,	NULL
Japan	NULL
Received	NULL
for	NULL
publication	NULL
July	NULL
20	NULL
,	NULL
1998	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
November	NULL
23	NULL
,	NULL
1998	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
Research	NULL
Grant	NULL
for	NULL
Immunology	NULL
,	NULL
Allergy	NULL
and	NULL
Organ	NULL
Transplant	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Health	NULL
and	NULL
Welfare	NULL
of	NULL
Japan	NULL
;	NULL
a	NULL
grant-in-aid	NULL
for	NULL
Scientific	NULL
Research	NULL
(	NULL
C	NULL
)	NULL
from	NULL
the	NULL
Ministry	NULL
of	NULL
Education	NULL
,	NULL
Science	NULL
,	NULL
Sports	NULL
,	NULL
and	NULL
Culture	NULL
of	NULL
Japan	NULL
;	NULL
an	NULL
Astra	NULL
Research	NULL
Grant	NULL
;	NULL
a	NULL
grant	NULL
from	NULL
Kanae	NULL
Foundation	NULL
for	NULL
Life	NULL
and	NULL
Socio-Medical	NULL
Science	NULL
;	NULL
and	NULL
Mitsubishi	NULL
Chemical	NULL
.	NULL

2	NULL
Address	NULL
correspondence	NULL
and	NULL
reprints	NULL
requests	NULL
to	NULL
Dr.	NULL
Kenji	NULL
Izuhara	NULL
,	NULL
Department	NULL
of	NULL
Clinical	NULL
Chemistry	NULL
and	NULL
Laboratory	NULL
Medicine	NULL
,	NULL
Faculty	NULL
of	NULL
Medicine	NULL
,	NULL
Kyushu	NULL
University	NULL
,	NULL
3-1-1	NULL
,	NULL
Maidashi	NULL
,	NULL
Higashi-ku	NULL
,	NULL
Fukuoka	NULL
,	NULL
812-8582	NULL
,	NULL
Japan	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
kizuhara	NULL
@	NULL
cclm.med.kyushu-u.ac.jp	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
gene	NULL
predisposing	NULL
to	NULL
atopy	NULL
,	NULL
and	NULL
by	NULL
the	NULL
possibility	NULL
that	NULL
several	NULL
genes	NULL
interact	NULL
with	NULL
a	NULL
strong	NULL
environmental	NULL
component	NULL
(	NULL
2	NULL
)	NULL
.	NULL

To	NULL
date	NULL
,	NULL
several	NULL
potential	NULL
linkages	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
correlate	NULL
with	NULL
atopy	NULL
(	NULL
2	NULL
)	NULL
,	NULL
among	NULL
them	NULL
the	NULL
IL-4R	NULL
a-chain	NULL
(	NULL
IL-4Ra®	NULL
;	NULL
Ref	NULL
.	NULL

3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

IL-4	NULL
is	NULL
a	NULL
pleiotropic	NULL
cytokine	NULL
,	NULL
essential	NULL
for	NULL
IgE	NULL
synthesis	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
differentiation	NULL
to	NULL
Th2	NULL
phenotype	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
)	NULL
.	NULL

IL-4	NULL
exerts	NULL
its	NULL
biological	NULL
activity	NULL
by	NULL
binding	NULL
to	NULL
the	NULL
target	NULL
cell	NULL
receptor	NULL
,	NULL
which	NULL
is	NULL
composed	NULL
of	NULL
a	NULL
heterodimer	NULL
of	NULL
IL-4R	NULL
«	NULL
and	NULL
the	NULL
common	NULL
y-chain	NULL
(	NULL
6	NULL
)	NULL
.	NULL

IL-4Ra	NULL
is	NULL
a	NULL
critical	NULL
component	NULL
for	NULL
the	NULL
binding	NULL
to	NULL
IL-4	NULL
and	NULL
signal	NULL
transduction	NULL
of	NULL
IL-4	NULL
(	NULL
7-11	NULL
)	NULL
.	NULL

Upon	NULL
stimulation	NULL
of	NULL
IL-4	NULL
,	NULL
Janus	NULL
tyrosine	NULL
kinase-1	NULL
and	NULL
3	NULL
are	NULL
activated	NULL
,	NULL
followed	NULL
by	NULL
activation	NULL
of	NULL
STAT6	NULL
,	NULL
which	NULL
has	NULL
a	NULL
central	NULL
role	NULL
in	NULL
IgE	NULL
synthesis	NULL
(	NULL
12-15	NULL
)	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
demonstrated	NULL
that	NULL
the	NULL
substitution	NULL
of	NULL
valine	NULL
(	NULL
Val	NULL
)	NULL
at	NULL
amino	NULL
acid	NULL
50	NULL
of	NULL
human	NULL
IL-4	NULL
(	NULL
hIL-4	NULL
)	NULL
Ra	NULL
for	NULL
isoleucine	NULL
(	NULL
Ile	NULL
)	NULL
augments	NULL
hIL-4	NULL
signals	NULL
in	NULL
B	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
patients	NULL
with	NULL
atopic	NULL
asthma	NULL
show	NULL
high	NULL
incidence	NULL
of	NULL
the	NULL
substitution	NULL
(	NULL
16	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
He	NULL
``	NULL
variant	NULL
of	NULL
hIL-4Ra	NULL
causes	NULL
atopy	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
another	NULL
variant	NULL
of	NULL
hIL-4Ra	NULL
carrying	NULL
arginine	NULL
(	NULL
Arg	NULL
)	NULL
at	NULL
551	NULL
(	NULL
num-bering	NULL
from	NULL
the	NULL
start	NULL
of	NULL
mature	NULL
protein	NULL
)	NULL
instead	NULL
of	NULL
glutamine	NULL
(	NULL
Gln	NULL
)	NULL
has	NULL
also	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
correlated	NULL
with	NULL
hyper	NULL
IgE	NULL
syndrome	NULL
and	NULL
severe	NULL
atopic	NULL
eczema	NULL
and	NULL
to	NULL
cause	NULL
up-regulation	NULL
of	NULL
CD23	NULL
expression	NULL
and	NULL
dissociation	NULL
with	NULL
a	NULL
tyrosine-phosphatase	NULL
,	NULL
SHP-1	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
two	NULL
studies	NULL
,	NULL
two	NULL
possibilities	NULL
arise	NULL
.	NULL

One	NULL
is	NULL
that	NULL
these	NULL
two	NULL
substitutions	NULL
act	NULL
independently	NULL
to	NULL
cause	NULL
atopy	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
an	NULL
individual	NULL
bearing	NULL
both	NULL
variants	NULL
would	NULL
belong	NULL
to	NULL
a	NULL
higher	NULL
risk	NULL
group	NULL
than	NULL
one	NULL
who	NULL
carries	NULL
each	NULL
single	NULL
variant	NULL
.	NULL

The	NULL
other	NULL
possibility	NULL
is	NULL
that	NULL
these	NULL
two	NULL
polymorphisms	NULL
are	NULL
linkage	NULL
disequi-librium	NULL
.	NULL

In	NULL
this	NULL
case	NULL
,	NULL
either	NULL
of	NULL
these	NULL
variants	NULL
simply	NULL
represents	NULL
a	NULL
marker	NULL
of	NULL
the	NULL
other	NULL
variant	NULL
.	NULL

It	NULL
is	NULL
important	NULL
to	NULL
address	NULL
this	NULL
point	NULL
,	NULL
to	NULL
estimate	NULL
the	NULL
quantity	NULL
of	NULL
risk	NULL
of	NULL
contracting	NULL
atopic	NULL
asthma	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
generated	NULL
transfectants	NULL
on	NULL
which	NULL
four	NULL
kinds	NULL
of	NULL
hIL-4Ra	NULL
,	NULL
carrying	NULL
either	NULL
Val	NULL
or	NULL
He	NULL
at	NULL
50	NULL
and	NULL
either	NULL
Gin	NULL
or	NULL
Arg	NULL
at	NULL
551	NULL
,	NULL
are	NULL
expressed	NULL
,	NULL
and	NULL
we	NULL
analyzed	NULL
responsiveness	NULL
to	NULL
hIL-4	NULL
.	NULL

We	NULL
further	NULL
assessed	NULL
the	NULL
genetic	NULL
association	NULL
of	NULL
the	NULL
substitution	NULL
Arg551Gin	NULL
with	NULL
atopic	NULL
asthma	NULL
,	NULL
and	NULL
CD23	NULL
expression	NULL
and	NULL
IgE	NULL
synthesis	NULL
induced	NULL
by	NULL
hIL-4	NULL
in	NULL
HNeSOVal-bearing	NULL
PBMC	NULL
.	NULL

3	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
IL-4Ra	NULL
@	NULL
,	NULL
IL-4R	NULL
a-chain	NULL
;	NULL
bIL-4	NULL
,	NULL
human	NULL
IL-4	NULL
;	NULL
mIL-3	NULL
,	NULL
mouse	NULL
IL-3	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility-shift	NULL
assay	NULL
.	NULL

0022-1767/99/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
1228	NULL
Materials	NULL
and	NULL
Methods	NULL
Site-directed	NULL
mutagenesis	NULL
Site-directed	NULL
mutagenesis	NULL
of	NULL
either	NULL
Val	NULL
at	NULL
50	NULL
amino	NULL
acid	NULL
with	NULL
le	NULL
,	NULL
or	NULL
Gin	NULL
at	NULL
551	NULL
with	NULL
Arg	NULL
in	NULL
the	NULL
hIL-4Ra	NULL
,	NULL
was	NULL
accomplished	NULL
using	NULL
oligonucleotide-mediated	NULL
mutagenesis	NULL
by	NULL
selection	NULL
using	NULL
the	NULL
uracil	NULL
technique	NULL
against	NULL
template	NULL
strands	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Oligonucleotides	NULL
used	NULL
for	NULL
mutagenesis	NULL
to	NULL
generate	NULL
mutations	NULL
of	NULL
the	NULL
223th	NULL
and	NULL
1727th	NULL
nucleic	NULL
acid	NULL
from	NULL
the	NULL
first	NULL
ATG	NULL
codon	NULL
were	NULL
5'-CTCAGGGATACACCG-3	NULL
'	NULL
and	NULL
5'-CAAACTCCCGATAGCCA-3	NULL
'	NULL
,	NULL
whose	NULL
mutated	NULL
nucleic	NULL
acids	NULL
are	NULL
under-lined	NULL
.	NULL

Plasmids	NULL
of	NULL
these	NULL
hIL-4Ras	NULL
were	NULL
inserted	NULL
into	NULL
pME18S	NULL
,	NULL
and	NULL
these	NULL
plasmids	NULL
were	NULL
denoted	NULL
val	NULL
``	NULL
Gin	NULL
``	NULL
``	NULL
,	NULL
val	NULL
``	NULL
0Arg55	NULL
'	NULL
,	NULL
He	NULL
``	NULL
``	NULL
GIn	NULL
``	NULL
``	NULL
,	NULL
and	NULL
e	NULL
``	NULL
``	NULL
respectively	NULL
.	NULL

Construction	NULL
of	NULL
transfected	NULL
B	NULL
cell	NULL
line	NULL
Four	NULL
kinds	NULL
of	NULL
plasmids	NULL
Val	NULL
``	NULL
®Arg	NULL
``	NULL
``	NULL
,	NULL
Ne®°Gin	NULL
``	NULL
``	NULL
,	NULL
and	NULL
Ie	NULL
``	NULL
were	NULL
transfected	NULL
by	NULL
electroporation	NULL
to	NULL
a	NULL
mouse	NULL
pro-B	NULL
cell	NULL
line	NULL
,	NULL
Ba/F3	NULL
,	NULL
and	NULL
drug-resistant	NULL
and	NULL
hIL-4-responsive	NULL
clones	NULL
were	NULL
selected	NULL
,	NULL
which	NULL
were	NULL
denoted	NULL
BF-Val	NULL
``	NULL
°GIn	NULL
``	NULL
``	NULL
,	NULL
BF—ValsoArgSSI	NULL
,	NULL
BF-He	NULL
``	NULL
°GIn*	NULL
``	NULL
``	NULL
,	NULL
and	NULL
BF-Ne	NULL
``	NULL
°Arg	NULL
``	NULL
``	NULL
'	NULL
,	NULL
respectively	NULL
.	NULL

These	NULL
transfectants	NULL
were	NULL
maintained	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
mouse	NULL
IL-3	NULL
(	NULL
mIL-3	NULL
)	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
T.	NULL
Hara	NULL
,	NULL
(	NULL
Tokyo	NULL
University	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Extraction	NULL
of	NULL
nuclear	NULL
proteins	NULL
and	NULL
electrophoretic	NULL
mobility-shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
Procedures	NULL
of	NULL
extraction	NULL
of	NULL
nuclear	NULL
proteins	NULL
and	NULL
EMSA	NULL
were	NULL
conducted	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
10	NULL
ng/ml	NULL
of	NULL
either	NULL
hIL-4	NULL
or	NULL
mIL-4	NULL
for	NULL
15	NULL
min	NULL
,	NULL
and	NULL
then	NULL
lysed	NULL
to	NULL
extract	NULL
nuclear	NULL
proteins	NULL
.	NULL

The	NULL
amounts	NULL
of	NULL
loaded	NULL
nuclear	NULL
extracts	NULL
were	NULL
normalized	NULL
before	NULL
mixing	NULL
.	NULL

The	NULL
oligonucleotide	NULL
probe	NULL
used	NULL
was	NULL
Ie	NULL
(	NULL
5-GTCAACTTCCCAA	NULL
GAACAGAA-3	NULL
'	NULL
)	NULL
.	NULL

Luciferase	NULL
activity	NULL
assay	NULL
The	NULL
plasmid	NULL
used	NULL
for	NULL
the	NULL
luciferase	NULL
activity	NULL
assay	NULL
was	NULL
constructed	NULL
by	NULL
pGL3-enhancer	NULL
vector	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
into	NULL
which	NULL
the	NULL
promoter	NULL
region	NULL
from	NULL
-187	NULL
to	NULL
+6	NULL
of	NULL
human	NULL
I€e	NULL
was	NULL
inserted	NULL
.	NULL

After	NULL
the	NULL
plasmid	NULL
was	NULL
electroporated	NULL
into	NULL
each	NULL
transfectant	NULL
,	NULL
followed	NULL
by	NULL
incubation	NULL
for	NULL
24	NULL
h	NULL
,	NULL
the	NULL
cells	NULL
were	NULL
further	NULL
incubated	NULL
with	NULL
2	NULL
ng/m	NULL
!	NULL

of	NULL
either	NULL
hIL-4	NULL
or	NULL
mIL-4	NULL
for	NULL
24	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
mIL-3	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
by	NULL
PBS	NULL
,	NULL
and	NULL
then	NULL
lysed	NULL
with	NULL
reporter	NULL
lysis	NULL
buffer	NULL
(	NULL
Toyoink	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
and	NULL
centrifuged	NULL
to	NULL
remove	NULL
debris	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
mixed	NULL
with	NULL
luciferse	NULL
assay	NULL
reagent	NULL
(	NULL
Toyoink	NULL
)	NULL
.	NULL

Binding	NULL
assay	NULL
Binding	NULL
of	NULL
[	NULL
**IJ-labeled	NULL
hIL-4	NULL
(	NULL
NEN	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
to	NULL
the	NULL
cells	NULL
was	NULL
assayed	NULL
as	NULL
described	NULL
before	NULL
(	NULL
20	NULL
)	NULL
.	NULL

After	NULL
the	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
[	NULL
**I	NULL
]	NULL
-labeled	NULL
hIL-4	NULL
for	NULL
3	NULL
h	NULL
at	NULL
4°C	NULL
,	NULL
bound	NULL
and	NULL
free	NULL
ligands	NULL
were	NULL
separated	NULL
by	NULL
centrifugation	NULL
through	NULL
an	NULL
oil	NULL
gradient	NULL
.	NULL

Nonspecific	NULL
binding	NULL
was	NULL
measured	NULL
by	NULL
adding	NULL
a	NULL
150-fold	NULL
molar	NULL
excess	NULL
of	NULL
nonradiolabeled	NULL
hIL-4	NULL
.	NULL

Immunoprecipitation	NULL
and	NULL
Western	NULL
blotting	NULL
Procedures	NULL
of	NULL
immunoprecipitation	NULL
and	NULL
Western	NULL
blotting	NULL
were	NULL
conducted	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
21	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
lysed	NULL
in	NULL
the	NULL
lysis	NULL
buffer	NULL
containing	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-hIL-4Ra	NULL
mAb	NULL
that	NULL
was	NULL
provided	NULL
by	NULL
Schering-France	NULL
(	NULL
Dardilly	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Proteins	NULL
eluted	NULL
by	NULL
boiling	NULL
with	NULL
SDS-PAGE	NULL
sample	NULL
buffer	NULL
were	NULL
applied	NULL
to	NULL
SDS-PAGE	NULL
and	NULL
transferred	NULL
electrophoretically	NULL
to	NULL
a	NULL
polyvinylidene	NULL
fluoride	NULL
membrane	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Proteins	NULL
were	NULL
probed	NULL
with	NULL
anti-hIL-4Ra	NULL
mAb	NULL
(	NULL
Genzyme	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
visualized	NULL
by	NULL
enhanced	NULL
chemi-luminescence	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Genetic	NULL
analysis	NULL
All	NULL
the	NULL
asthmatic	NULL
subjects	NULL
had	NULL
been	NULL
diagnosed	NULL
by	NULL
physicians	NULL
specializing	NULL
in	NULL
asthma	NULL
,	NULL
with	NULL
1	NULL
)	NULL
recurrent	NULL
breathlessness	NULL
and	NULL
chest	NULL
tightness	NULL
requiring	NULL
ongoing	NULL
treatment	NULL
,	NULL
2	NULL
)	NULL
physician-documented	NULL
wheeze	NULL
,	NULL
and	NULL
3	NULL
)	NULL
documented	NULL
la-bile	NULL
airflow	NULL
obstruction	NULL
with	NULL
variability	NULL
in	NULL
serial	NULL
peak	NULL
expiratory	NULL
flow	NULL
rates	NULL
>	NULL
30	NULL
%	NULL
.	NULL

Specific	NULL
IgE	NULL
was	NULL
detected	NULL
by	NULL
MAST	NULL
(	NULL
Hitachi	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Atopy	NULL
was	NULL
diagnosed	NULL
as	NULL
the	NULL
presence	NULL
of	NULL
high	NULL
concentration	NULL
of	NULL
total	NULL
serum	NULL
IgE	NULL
,	NULL
a	NULL
positive	NULL
specific	NULL
IgE	NULL
titer	NULL
against	NULL
one	NULL
or	NULL
more	NULL
of	NULL
15	NULL
highly	NULL
purified	NULL
aeroallergens	NULL
or	NULL
a	NULL
combination	NULL
of	NULL
these	NULL
two	NULL
features	NULL
.	NULL

DNA	NULL
samples	NULL
were	NULL
extracted	NULL
using	NULL
a	NULL
commercial	NULL
kit	NULL
(	NULL
IsoQuick	NULL
,	NULL
Mi-croprobe	NULL
,	NULL
Garden	NULL
Grove	NULL
,	NULL
WA	NULL
)	NULL
.	NULL

The	NULL
PCR	NULL
reaction	NULL
was	NULL
performed	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
genomic	NULL
DNA	NULL
as	NULL
template	NULL
after	NULL
an	NULL
initial	NULL
5	NULL
min	NULL
denaturation	NULL
at	NULL
94°C	NULL
,	NULL
CUTTING	NULL
EDGE	NULL
followed	NULL
by	NULL
40	NULL
cycles	NULL
of	NULL
94°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
60°C	NULL
for	NULL
30	NULL
s	NULL
,	NULL
and	NULL
72°C	NULL
for	NULL
15	NULL
s.	NULL
The	NULL
primers	NULL
to	NULL
detect	NULL
HMeSOVal	NULL
were	NULL
5'-GAAGCCCACACGTGTA	NULL
for	NULL
e	NULL
``	NULL
``	NULL
,	NULL
5-GAAGCCCACACGTGTG	NULL
for	NULL
Val	NULL
``	NULL
``	NULL
,	NULL
and	NULL
GAAGGAG	NULL
.	NULL

The	NULL
primers	NULL
for	NULL
Arg551GIn	NULL
were	NULL
5	NULL
``	NULL
-GTCTCGGCCCCCAC	NULL
CACCGGCTATC	NULL
and	NULL
5'-ACCCAAGCCCACCACCGCACT	NULL
.	NULL

Underlined	NULL
nucleotides	NULL
were	NULL
exchanged	NULL
to	NULL
incorporate	NULL
the	NULL
polymorphic	NULL
site	NULL
into	NULL
a	NULL
Bsil	NULL
recognition	NULL
site	NULL
.	NULL

All	NULL
three	NULL
genotypes	NULL
for	NULL
each	NULL
substitution	NULL
were	NULL
confirmed	NULL
by	NULL
sequencing	NULL
randomly	NULL
selected	NULL
from	NULL
each	NULL
genotype	NULL
.	NULL

The	NULL
whole	NULL
data	NULL
set	NULL
was	NULL
scored	NULL
blind	NULL
.	NULL

Measurement	NULL
of	NULL
CD23	NULL
expression	NULL
and	NULL
IgE	NULL
,	NULL
synthesis	NULL
Heparinized	NULL
blood	NULL
samples	NULL
were	NULL
collected	NULL
from	NULL
10	NULL
adult	NULL
volunteers	NULL
,	NULL
all	NULL
of	NULL
who	NULL
were	NULL
ascertained	NULL
not	NULL
to	NULL
have	NULL
any	NULL
allergic	NULL
history	NULL
,	NULL
to	NULL
show	NULL
normal	NULL
serum	NULL
IgE	NULL
level	NULL
,	NULL
and	NULL
to	NULL
be	NULL
negative	NULL
in	NULL
a	NULL
radioallergosorbent	NULL
test	NULL
for	NULL
airborn	NULL
allergens	NULL
.	NULL

PBMC	NULL
was	NULL
isolated	NULL
by	NULL
Ficoll-sodium	NULL
metrizoate	NULL
sedimentation	NULL
(	NULL
Organon	NULL
Teknika	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
.	NULL

Genotype	NULL
of	NULL
HNeSOVal	NULL
was	NULL
confirmed	NULL
by	NULL
sequencing	NULL
.	NULL

Measurement	NULL
of	NULL
CD23	NULL
expression	NULL
on	NULL
CD20+*	NULL
B	NULL
cells	NULL
was	NULL
analyzed	NULL
,	NULL
as	NULL
described	NULL
before	NULL
(	NULL
23	NULL
)	NULL
.	NULL

PBMC	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
2.5	NULL
ng/ml	NULL
hIL-4	NULL
for	NULL
48	NULL
h	NULL
were	NULL
incubated	NULL
with	NULL
biotinylated	NULL
anti-CD23	NULL
mAb	NULL
,	NULL
followed	NULL
by	NULL
incubation	NULL
with	NULL
phycoerythrin-conjugated	NULL
streptavidin	NULL
and	NULL
FITC-conjugated	NULL
anti-CD20	NULL
mAb	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
San	NULL
Jose	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Iso-type-matched	NULL
control	NULL
mAbs	NULL
were	NULL
used	NULL
for	NULL
a	NULL
negative	NULL
staining	NULL
.	NULL

Stained	NULL
cells	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
on	NULL
a	NULL
FACScan	NULL
using	NULL
a	NULL
gate	NULL
for	NULL
CD20*	NULL
B	NULL
cells	NULL
.	NULL

Measurement	NULL
of	NULL
IgE	NULL
synthesis	NULL
was	NULL
conducted	NULL
as	NULL
described	NULL
before	NULL
(	NULL
24	NULL
)	NULL
.	NULL

After	NULL
PBMC	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
5	NULL
ng/ml	NULL
hIL-4	NULL
for	NULL
14	NULL
days	NULL
,	NULL
IgE	NULL
in	NULL
culture	NULL
supernatants	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
solid-phase	NULL
RIA	NULL
,	NULL
and	NULL
net	NULL
IgE	NULL
synthesis	NULL
was	NULL
calculated	NULL
by	NULL
subtracting	NULL
the	NULL
value	NULL
of	NULL
preformed	NULL
IgE	NULL
.	NULL

To	NULL
estimate	NULL
preformed	NULL
IgE	NULL
,	NULL
both	NULL
50	NULL
ug/ml	NULL
of	NULL
cyclohexi-mide	NULL
and	NULL
10	NULL
pg/ml	NULL
of	NULL
puromycin	NULL
were	NULL
added	NULL
.	NULL

Results	NULL
and	NULL
Discussion	NULL
STAT6	NULL
activation	NULL
of	NULL
the	NULL
variants	NULL
It	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
STAT6	NULL
has	NULL
a	NULL
central	NULL
role	NULL
for	NULL
germline	NULL
e	NULL
transcript	NULL
induced	NULL
by	NULL
IL-4	NULL
,	NULL
based	NULL
on	NULL
studies	NULL
of	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
Ie	NULL
,	NULL
and	NULL
STAT6-disruption	NULL
mice	NULL
(	NULL
12-15	NULL
)	NULL
.	NULL

We	NULL
have	NULL
also	NULL
shown	NULL
that	NULL
the	NULL
He	NULL
``	NULL
variant	NULL
augmented	NULL
STAT6	NULL
activation	NULL
induced	NULL
by	NULL
IL-4	NULL
(	NULL
16	NULL
)	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
we	NULL
analyzed	NULL
STAT6	NULL
activation	NULL
induced	NULL
by	NULL
hIL-4	NULL
in	NULL
the	NULL
variants	NULL
to	NULL
investigate	NULL
whether	NULL
activation	NULL
of	NULL
a	NULL
signal-transducing	NULL
molecule	NULL
for	NULL
generation	NULL
of	NULL
germline	NULL
e	NULL
transcript	NULL
is	NULL
enhanced	NULL
by	NULL
the	NULL
Arg551GIn	NULL
variant	NULL
.	NULL

The	NULL
STAT6	NULL
activities	NULL
in	NULL
BF-Ne	NULL
``	NULL
°Gin	NULL
``	NULL
``	NULL
'	NULL
and	NULL
BF-Ile	NULL
``	NULL
°Arg	NULL
``	NULL
``	NULL
'	NULL
were	NULL
up-regulated	NULL
compared	NULL
with	NULL
those	NULL
of	NULL
and	NULL
BF-Val	NULL
``	NULL
°Arg	NULL
>	NULL
``	NULL
'	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
image	NULL
analyzer	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
;	NULL
1.6-	NULL
and	NULL
1.8-fold	NULL
,	NULL
the	NULL
averages	NULL
of	NULL
three	NULL
experiments	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
whereas	NULL
those	NULL
of	NULL
BF-Val	NULL
``	NULL
°Arg	NULL
``	NULL
``	NULL
'	NULL
and	NULL
BF-Ne	NULL
``	NULL
Arg	NULL
``	NULL
``	NULL
*	NULL
were	NULL
invariable	NULL
with	NULL
those	NULL
of	NULL
BF-Val	NULL
``	NULL
°Gin	NULL
``	NULL
``	NULL
'	NULL
and	NULL
BF-NMe	NULL
``	NULL
``	NULL
GIn	NULL
``	NULL
``	NULL
'	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
;	NULL
0.8-	NULL
and	NULL
0.9-fold	NULL
,	NULL
the	NULL
averages	NULL
of	NULL
three	NULL
experiments	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

There	NULL
was	NULL
no	NULL
difference	NULL
of	NULL
the	NULL
STAT6	NULL
activities	NULL
induced	NULL
by	NULL
mIL-4	NULL
(	NULL
Fig	NULL
.	NULL

1B	NULL
)	NULL
.	NULL

These	NULL
results	NULL
confirmed	NULL
our	NULL
previous	NULL
finding	NULL
that	NULL
STAT6	NULL
activation	NULL
by	NULL
hIL-4	NULL
is	NULL
increased	NULL
by	NULL
Ne	NULL
``	NULL
°	NULL
variant	NULL
(	NULL
16	NULL
)	NULL
.	NULL

As	NULL
Khurana	NULL
Hershey	NULL
et	NULL
al	NULL
.	NULL

stated	NULL
,	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
the	NULL
substitution	NULL
Arg551GIn	NULL
influences	NULL
STAT6	NULL
activation	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Transcription	NULL
activity	NULL
of	NULL
the	NULL
I¢	NULL
promoter	NULL
of	NULL
the	NULL
variants	NULL
In	NULL
our	NULL
previous	NULL
study	NULL
,	NULL
it	NULL
was	NULL
demonstrated	NULL
that	NULL
the	NULL
He	NULL
``	NULL
variant	NULL
up-regulates	NULL
the	NULL
transcription	NULL
activity	NULL
of	NULL
the	NULL
Ie	NULL
promoter	NULL
by	NULL
hIL-4	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Although	NULL
Arg551GIn	NULL
does	NULL
not	NULL
influence	NULL
STAT6	NULL
activation	NULL
,	NULL
it	NULL
would	NULL
be	NULL
still	NULL
possible	NULL
that	NULL
this	NULL
substitution	NULL
augments	NULL
the	NULL
transcription	NULL
activity	NULL
of	NULL
the	NULL
Ie	NULL
promoter	NULL
,	NULL
through	NULL
another	NULL
pathway	NULL
independent	NULL
of	NULL
that	NULL
of	NULL
Jak/STAT	NULL
.	NULL

To	NULL
address	NULL
this	NULL
point	NULL
,	NULL
we	NULL
next	NULL
measured	NULL
luciferase	NULL
activity	NULL
induced	NULL
by	NULL
hIL-4	NULL
and	NULL
mIL-4	NULL
in	NULL
the	NULL
variants	NULL
.	NULL

We	NULL
first	NULL
analyzed	NULL
the	NULL
proliferation	NULL
activity	NULL
of	NULL
the	NULL
variants	NULL
by	NULL
hIL-4	NULL
.	NULL

The	NULL
proliferations	NULL
by	NULL
hIL-4	NULL
in	NULL
BF-Ile	NULL
``	NULL
°GIn°	NULL
``	NULL
'	NULL
and	NULL
BF-Ne	NULL
``	NULL
were	NULL
up-regulated	NULL
compared	NULL
with	NULL
BF-Val	NULL
``	NULL
°Gin	NULL
``	NULL
``	NULL
'	NULL
and	NULL
BF-Val	NULL
``	NULL
®Arg	NULL
``	NULL
``	NULL
``	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
;	NULL
1.5-	NULL
and	NULL
1.9-fold	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

The	NULL
proliferations	NULL
of	NULL
BF-Val	NULL
``	NULL
°Gin	NULL
``	NULL
``	NULL
'	NULL
and	NULL
BF-Val	NULL
``	NULL
®Arg	NULL
``	NULL
``	NULL
'	NULL
,	NULL
or	NULL
of	NULL
BF-Ne	NULL
``	NULL
°GIn	NULL
``	NULL
``	NULL
'	NULL
and	NULL
BF-lle	NULL
``	NULL
°Arg	NULL
``	NULL
``	NULL
'	NULL
,	NULL
were	NULL
almost	NULL
the	NULL
same	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
,	NULL
and	NULL
the	NULL
proliferations	NULL
by	NULL
mIL-4	NULL
in	NULL
the	NULL
variants	NULL
were	NULL
invariable	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
hIL-4	NULL
_	NULL
~	NULL
FIGURE	NULL
1	NULL
.	NULL

-	NULL
Activation	NULL
of	NULL
STAT6	NULL
induced	NULL
by	NULL
hIL-4	NULL
in	NULL
the	NULL
variants	NULL
.	NULL

BE-Val	NULL
``	NULL
°GIn	NULL
``	NULL
``	NULL
``	NULL
(	NULL
VQ	NULL
)	NULL
,	NULL
BF-Val	NULL
``	NULL
Arg	NULL
``	NULL
``	NULL
(	NULL
VR	NULL
)	NULL
,	NULL
(	NULL
IQ	NULL
)	NULL
,	NULL
and	NULL
(	NULL
IR	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
ng/ml	NULL
of	NULL
either	NULL
hIL-4	NULL
or	NULL
mIL-4	NULL
for	NULL
15	NULL
min	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
positions	NULL
of	NULL
the	NULL
DNA	NULL
complex	NULL
with	NULL
STAT6	NULL
.	NULL

(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
results	NULL
,	NULL
we	NULL
performed	NULL
the	NULL
luciferase	NULL
assay	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
mIL-3	NULL
to	NULL
normalize	NULL
the	NULL
analyzed	NULL
cells	NULL
.	NULL

The	NULL
relative	NULL
transcription	NULL
activities	NULL
in	NULL
BE-Ile	NULL
``	NULL
°Gin	NULL
``	NULL
``	NULL
'	NULL
and	NULL
induced	NULL
by	NULL
hIL-4	NULL
were	NULL
higher	NULL
than	NULL
those	NULL
of	NULL
BF-Val	NULL
``	NULL
°GIn°	NULL
``	NULL
'	NULL
and	NULL
BF-Val	NULL
``	NULL
®Arg	NULL
``	NULL
``	NULL
'	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
;	NULL
1.5-	NULL
and	NULL
1.6-fold	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
whereas	NULL
those	NULL
of	NULL
BF-Val	NULL
``	NULL
®Arg	NULL
``	NULL
``	NULL
'	NULL
and	NULL
BF-INle	NULL
``	NULL
°Arg	NULL
``	NULL
``	NULL
'	NULL
were	NULL
invariable	NULL
with	NULL
those	NULL
of	NULL
BF-Val	NULL
``	NULL
°Gin	NULL
``	NULL
``	NULL
'	NULL
and	NULL
BF-Ile	NULL
``	NULL
°GiIn	NULL
``	NULL
``	NULL
'	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
;	NULL
1.1-	NULL
and	NULL
1.1-fold	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

The	NULL
relative	NULL
transcription	NULL
activities	NULL
in	NULL
the	NULL
variants	NULL
induced	NULL
by	NULL
mIL-4	NULL
were	NULL
invariable	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

The	NULL
proliferations	NULL
of	NULL
the	NULL
variants	NULL
in	NULL
this	NULL
condition	NULL
were	NULL
the	NULL
same	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
revealed	NULL
that	NULL
although	NULL
it	NULL
was	NULL
A	NULL
0.3	NULL
a	NULL
€	NULL
0.2	NULL
a	NULL
ag	NULL
--	NULL
o	NULL
--	NULL
VR	NULL
0	NULL
#	NULL
3	NULL
€	NULL
-A-	NULL
19	NULL
2	NULL
&	NULL
--	NULL
A~-	NULL
IR	NULL
i	NULL
-	NULL
01	NULL
L	NULL
0	NULL
.	NULL

.	NULL

r	NULL
a	NULL
:	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
hIL-4	NULL
(	NULL
ng/m	NULL
!	NULL
)	NULL

J	NULL
{	NULL
C	NULL
i460	NULL
miL.-4	NULL
I	NULL
hIL-4	NULL
Relative	NULL
Luciferase	NULL
Activity	NULL
FIGURE	NULL
2	NULL
.	NULL

Luciferase	NULL
activity	NULL
induced	NULL
by	NULL
hIL-4	NULL
in	NULL
the	NULL
variants	NULL
.	NULL

BF-val	NULL
``	NULL
°GIn	NULL
``	NULL
``	NULL
``	NULL
(	NULL
VQ	NULL
)	NULL
,	NULL
BF-Val®Arg	NULL
``	NULL
``	NULL
'	NULL
(	NULL
VR	NULL
)	NULL
,	NULL
BF-Ile	NULL
``	NULL
*	NULL
``	NULL
Gin	NULL
``	NULL
``	NULL
'	NULL
(	NULL
IQ	NULL
)	NULL
,	NULL
and	NULL
BF-	NULL
(	NULL
IR	NULL
)	NULL
,	NULL
with	NULL
which	NULL
the	NULL
reporter	NULL
gene	NULL
containing	NULL
the	NULL
promoter	NULL
region	NULL
of	NULL
human	NULL
Ie	NULL
were	NULL
transiently	NULL
transfected	NULL
,	NULL
were	NULL
incubated	NULL
with	NULL
2	NULL
ng/ml	NULL
of	NULL
either	NULL
hIL-4	NULL
or	NULL
mIL-4	NULL
for	NULL
24	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
mIL-3	NULL
.	NULL

The	NULL
relative	NULL
luciferase	NULL
activity	NULL
was	NULL
estimated	NULL
,	NULL
compared	NULL
with	NULL
the	NULL
value	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IL-4	NULL
.	NULL

Each	NULL
experiment	NULL
was	NULL
done	NULL
with	NULL
two	NULL
samples	NULL
,	NULL
and	NULL
the	NULL
mean	NULL
values	NULL
of	NULL
three	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

+	NULL
1229	NULL
VR	NULL
_	NULL
IQ	NULL
_	NULL
IR	NULL
vQ	NULL
-	NULL
VR	NULL
_	NULL
IQ	NULL
-	NULL
IR	NULL
f	NULL
#	NULL
_-	NULL
4	NULL
-	NULL
+	NULL
mIL-4	NULL
|=	NULL
+o=	NULL
+	NULL
=-	NULL
+	NULL
-+	NULL
H	NULL
u	NULL
--	NULL
‘	NULL
M	NULL
'	NULL
reproducible	NULL
that	NULL
the	NULL
He	NULL
``	NULL
variant	NULL
augmented	NULL
the	NULL
transcription	NULL
activity	NULL
of	NULL
Ie	NULL
promoter	NULL
induced	NULL
by	NULL
hIL-4	NULL
,	NULL
the	NULL
Arg551GIn	NULL
variant	NULL
did	NULL
not	NULL
elicit	NULL
a	NULL
clear	NULL
change	NULL
.	NULL

It	NULL
has	NULL
been	NULL
unclear	NULL
how	NULL
Arg551GIn	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
hyper	NULL
IgE	NULL
syndrome	NULL
and	NULL
severe	NULL
eczema	NULL
.	NULL

Because	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
IL-4	NULL
induces	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
various	NULL
intracellular	NULL
proteins	NULL
(	NULL
21	NULL
)	NULL
,	NULL
further	NULL
studies	NULL
focused	NULL
on	NULL
identifying	NULL
the	NULL
target	NULL
of	NULL
SHP-1	NULL
,	NULL
whose	NULL
association	NULL
with	NULL
IL-4Ra	NULL
is	NULL
less	NULL
in	NULL
Arg	NULL
``	NULL
``	NULL
*	NULL
type	NULL
than	NULL
in	NULL
Gin®	NULL
``	NULL
'	NULL
type	NULL
,	NULL
would	NULL
be	NULL
useful	NULL
.	NULL

Binding	NULL
activity	NULL
and	NULL
hIL-4Ra	NULL
expression	NULL
of	NULL
the	NULL
variants	NULL
In	NULL
our	NULL
previous	NULL
study	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
the	NULL
NeSOVal	NULL
variant	NULL
does	NULL
not	NULL
influence	NULL
the	NULL
binding	NULL
affinity	NULL
of	NULL
hIL-4Ra	NULL
with	NULL
hIL-4	NULL
(	NULL
16	NULL
)	NULL
.	NULL

We	NULL
next	NULL
performed	NULL
the	NULL
binding	NULL
assay	NULL
using	NULL
the	NULL
variants	NULL
.	NULL

The	NULL
values	NULL
of	NULL
K	NULL
,	NULL
,	NULL
were	NULL
not	NULL
varied	NULL
by	NULL
the	NULL
substitution	NULL
NeSOVal	NULL
,	NULL
as	NULL
described	NULL
previously	NULL
,	NULL
whereas	NULL
the	NULL
substitution	NULL
Arg551GIn	NULL
slightly	NULL
increased	NULL
the	NULL
values	NULL
of	NULL
K	NULL
,	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
;	NULL
BF-Val	NULL
``	NULL
°GIn	NULL
``	NULL
``	NULL
'	NULL
,	NULL
BF-Val	NULL
``	NULL
Arg	NULL
``	NULL
``	NULL
'	NULL
,	NULL
BF-Ne	NULL
``	NULL
°GIn*	NULL
``	NULL
'	NULL
,	NULL
and	NULL
BF-NMle	NULL
``	NULL
°Arg	NULL
``	NULL
``	NULL
*	NULL
:	NULL
1.3	NULL
X	NULL
10	NULL
,	NULL
2.3	NULL
X	NULL
10	NULL
,	NULL
1.5	NULL
X	NULL
10	NULL
,	NULL
and	NULL
2.1	NULL
X	NULL
10	NULL
pM	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
higher	NULL
responsiveness	NULL
to	NULL
hIL-4	NULL
in	NULL
the	NULL
Ile	NULL
``	NULL
type	NULL
is	NULL
not	NULL
explained	NULL
by	NULL
higher	NULL
affinity	NULL
of	NULL
the	NULL
receptor	NULL
with	NULL
hIL-4	NULL
in	NULL
that	NULL
type	NULL
.	NULL

The	NULL
receptors	NULL
expressed	NULL
on	NULL
the	NULL
surfaces	NULL
of	NULL
these	NULL
four	NULL
clones	NULL
were	NULL
invariable	NULL
,	NULL
as	NULL
A	NULL
3	NULL
E	NULL
-O-	NULL
vQ	NULL
g	NULL
-A-	NULL
VR	NULL
w	NULL
-	NULL
@	NULL
-	NULL
1Q	NULL
&	NULL
5	NULL
ro	NULL
o	NULL
E	NULL
w	NULL
a	NULL
Bound	NULL
(	NULL
fmol/10	NULL
6	NULL
cells	NULL
)	NULL
B	NULL
va	NULL
vr	NULL
10	NULL
IR	NULL
¢	NULL
**	NULL
«	NULL
*	NULL
»	NULL
--	NULL
-	NULL
IL-4R	NULL
FIGURE	NULL
3	NULL
.	NULL

Binding	NULL
activity	NULL
and	NULL
hIL-4Ra	NULL
«	NULL
expression	NULL
of	NULL
the	NULL
variants	NULL
.	NULL

A	NULL
,	NULL
Binding	NULL
of	NULL
[	NULL
'**IJ-labeled	NULL
hIL-4	NULL
to	NULL
BF-Val	NULL
``	NULL
°GIn	NULL
``	NULL
``	NULL
*	NULL
(	NULL
VQ	NULL
;	NULL
open	NULL
circle	NULL
)	NULL
,	NULL
BF-Val	NULL
``	NULL
(	NULL
VR	NULL
;	NULL
open	NULL
triangle	NULL
)	NULL
,	NULL
(	NULL
IQ	NULL
;	NULL
closed	NULL
circle	NULL
)	NULL
,	NULL
and	NULL
(	NULL
IR	NULL
;	NULL
closed	NULL
triangle	NULL
)	NULL
was	NULL
assayed	NULL
.	NULL

B	NULL
,	NULL
Immunoprecipitates	NULL
with	NULL
anti-hIL-4Ra	NULL
mAb	NULL
from	NULL
BF-Val	NULL
``	NULL
°GIn	NULL
``	NULL
``	NULL
``	NULL
(	NULL
VQ	NULL
)	NULL
,	NULL
BF-Val	NULL
``	NULL
®Arg	NULL
``	NULL
``	NULL
(	NULL
VR	NULL
)	NULL
,	NULL
BF-Ile®	NULL
``	NULL
Gin°	NULL
``	NULL
``	NULL
'	NULL
(	NULL
IQ	NULL
)	NULL
,	NULL
and	NULL
BF-Nle	NULL
``	NULL
Arg	NULL
>	NULL
>	NULL
*	NULL
(	NULL
IR	NULL
)	NULL
were	NULL
probed	NULL
with	NULL
anti-hIL-4Ra	NULL
mAb	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
1230	NULL
CUTTING	NULL
EDGE	NULL
Table	NULL
I	NULL
.	NULL

-	NULL
Genotype	NULL
frequencies	NULL
at	NULL
position	NULL
50	NULL
and	NULL
551	NULL
in	NULL
the	NULL
IL-4Ra	NULL
gene	NULL
by	NULL
symptoms	NULL
,	NULL
total	NULL
IgE	NULL
,	NULL
and	NULL
specific	NULL
IgE	NULL
levels	NULL
Genotype	NULL
at	NULL
Position	NULL
50	NULL
Genotype	NULL
at	NULL
Position	NULL
551	NULL
Ne	NULL
``	NULL
,	NULL
Ie	NULL
``	NULL
,	NULL
-	NULL
Val	NULL
``	NULL
Odds	NULL
``	NULL
Arg	NULL
``	NULL
``	NULL
``	NULL
/	NULL
-	NULL
Arg	NULL
``	NULL
-	NULL
Gin	NULL
``	NULL
Odds	NULL
``	NULL
Phenotype	NULL
n	NULL
e	NULL
``	NULL
``	NULL
-	NULL
val	NULL
``	NULL
-	NULL
val	NULL
``	NULL
(	NULL
95	NULL
%	NULL
C1	NULL
)	NULL
p	NULL
Arg	NULL
``	NULL
_	NULL
Gln	NULL
``	NULL
_	NULL
Gin	NULL
``	NULL
(	NULL
95	NULL
%	NULL
CD	NULL
p	NULL
Control	NULL
100	NULL
18	NULL
46	NULL
36	NULL
1	NULL
21	NULL
78	NULL
Asthmatics	NULL
Atopic	NULL
adult	NULL
100	NULL
59	NULL
27	NULL
14	NULL
6.59	NULL
<	NULL
0.0001	NULL
2	NULL
30	NULL
68	NULL
1.66	NULL
0.111	NULL
(	NULL
3.07-14.2	NULL
)	NULL
(	NULL
0.88-3.13	NULL
)	NULL
Atopic	NULL
child	NULL
100	NULL
60	NULL
28	NULL
12	NULL
6.83	NULL
<	NULL
0.0001	NULL
1	NULL
26	NULL
73	NULL
1.31	NULL
0.411	NULL
(	NULL
3.58-13.1	NULL
)	NULL
(	NULL
0.69-2.50	NULL
)	NULL
Nonatopic	NULL
adult	NULL
100	NULL
16	NULL
50	NULL
34	NULL
1.00	NULL
4	NULL
20	NULL
76	NULL
1.12	NULL
0.737	NULL
(	NULL
0.58-2.17	NULL
)	NULL
Low	NULL
total	NULL
IgE	NULL
(	NULL
<	NULL
400	NULL
IU/ml	NULL
)	NULL
levels	NULL
_	NULL
170	NULL
30	NULL
80	NULL
60	NULL
5	NULL
35	NULL
130	NULL
High	NULL
total	NULL
IgE	NULL
(	NULL
>	NULL
400	NULL
IU/ml	NULL
)	NULL
levels	NULL
230	NULL
-	NULL
123	NULL
71	NULL
36	NULL
3.09	NULL
<	NULL
0.0001	NULL
3	NULL
62	NULL
165	NULL
1.28	NULL
0.288	NULL
(	NULL
1.98-4.91	NULL
)	NULL
(	NULL
0.81-2.02	NULL
)	NULL
Mite	NULL
Ab	NULL
negative	NULL
165	NULL
30	NULL
75	NULL
60	NULL
5	NULL
34	NULL
126	NULL
Mite	NULL
Ab	NULL
positive	NULL
235	NULL
123	NULL
76	NULL
36	NULL
3.17	NULL
<	NULL
0.0001	NULL
3	NULL
63	NULL
169	NULL
1.26	NULL
0.319	NULL
(	NULL
1.98-5.07	NULL
)	NULL
(	NULL
0.63-2.52	NULL
)	NULL
``	NULL
Tee	NULL
vs	NULL
Ne/Val	NULL
``	NULL
°	NULL
+	NULL
Val	NULL
``	NULL
val	NULL
``	NULL
bArgSSI/ArgSSI	NULL
4	NULL
Arg551/Gln551	NULL
vs	NULL
Gin	NULL
/GIn**	NULL
estimated	NULL
by	NULL
the	NULL
binding	NULL
assay	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
;	NULL
3100-4200/cell	NULL
)	NULL
and	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
higher	NULL
responsiveness	NULL
to	NULL
hIL-4	NULL
in	NULL
the	NULL
He	NULL
``	NULL
type	NULL
is	NULL
not	NULL
due	NULL
to	NULL
the	NULL
high	NULL
expression	NULL
of	NULL
the	NULL
receptor	NULL
on	NULL
the	NULL
surface	NULL
.	NULL

To	NULL
date	NULL
,	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
the	NULL
Ne	NULL
``	NULL
variant	NULL
up-regulates	NULL
the	NULL
hIL-4	NULL
signals	NULL
remains	NULL
unresolved	NULL
.	NULL

As	NULL
for	NULL
mIL-4Ra	NULL
,	NULL
the	NULL
substitution	NULL
of	NULL
threonine	NULL
(	NULL
Thr	NULL
)	NULL
at	NULL
amino	NULL
acid	NULL
49	NULL
to	NULL
Ile	NULL
enhances	NULL
dissociation	NULL
of	NULL
mIL-4	NULL
from	NULL
mIL-4R	NULL
«	NULL
a	NULL
,	NULL
probably	NULL
by	NULL
abrogating	NULL
one	NULL
N-glycosylation	NULL
site	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Although	NULL
NeSOVal	NULL
is	NULL
not	NULL
involved	NULL
in	NULL
glycosylation	NULL
of	NULL
hIL-4Ra	NULL
,	NULL
it	NULL
would	NULL
be	NULL
possible	NULL
that	NULL
Thr49lle	NULL
of	NULL
mIL-4Ra	NULL
«	NULL
and	NULL
NeSOVal	NULL
of	NULL
hIL-4Ra	NULL
cause	NULL
up-regula-	NULL
A	NULL
A	NULL
MFI	NULL
(	NULL
IL-4	NULL
-	NULL
Fresh	NULL
)	NULL
FIGURE	NULL
4	NULL
.	NULL

CD23	NULL
Expression	NULL
and	NULL
IgE	NULL
synthesis	NULL
of	NULL
PBMC	NULL
genotyped	NULL
on	NULL
HeSOVal	NULL
.	NULL

A	NULL
,	NULL
He-	NULL
or	NULL
Val-bearing	NULL
PBMCs	NULL
from	NULL
each	NULL
of	NULL
five	NULL
donors	NULL
were	NULL
stimulated	NULL
by	NULL
2.5	NULL
ng/ml	NULL
of	NULL
hIL-4	NULL
for	NULL
48	NULL
h	NULL
,	NULL
and	NULL
the	NULL
mean	NULL
AMFI	NULL
of	NULL
CD23	NULL
expression	NULL
on	NULL
CD20*	NULL
B	NULL
cells	NULL
was	NULL
evaluated	NULL
.	NULL

AMFI	NULL
was	NULL
calculated	NULL
by	NULL
subtracting	NULL
the	NULL
value	NULL
of	NULL
fresh	NULL
cells	NULL
from	NULL
the	NULL
value	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IL-4	NULL
.	NULL

Typical	NULL
examples	NULL
of	NULL
flow	NULL
cytometry	NULL
were	NULL
shown	NULL
.	NULL

B	NULL
,	NULL
He-	NULL
or	NULL
Val	NULL
``	NULL
PBMCs	NULL
from	NULL
each	NULL
of	NULL
five	NULL
donors	NULL
were	NULL
stimulated	NULL
by	NULL
5	NULL
ng/ml	NULL
of	NULL
hIL-4	NULL
for	NULL
14	NULL
days	NULL
,	NULL
and	NULL
the	NULL
synthesized	NULL
IgE	NULL
was	NULL
assessed	NULL
.	NULL

*	NULL
,	NULL
Statistically	NULL
significant	NULL
difference	NULL
at	NULL
p	NULL
<	NULL
0.05.	NULL
tion	NULL
of	NULL
the	NULL
IL-4	NULL
signals	NULL
by	NULL
similar	NULL
mechanisms	NULL
,	NULL
as	NULL
both	NULL
amino	NULL
acids	NULL
are	NULL
adjacent	NULL
to	NULL
one	NULL
cysteine	NULL
positionally	NULL
conserved	NULL
in	NULL
the	NULL
cytokine	NULL
receptor	NULL
family	NULL
.	NULL

Genetic	NULL
analysis	NULL
of	NULL
Arg551GIn	NULL
in	NULL
atopic	NULL
asthma	NULL
To	NULL
address	NULL
the	NULL
genetic	NULL
correlation	NULL
of	NULL
Arg551GIn	NULL
with	NULL
atopic	NULL
asthma	NULL
,	NULL
we	NULL
next	NULL
conducted	NULL
a	NULL
genetic	NULL
association	NULL
study	NULL
in	NULL
a	NULL
Japanese	NULL
population	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
.	NULL

As	NULL
previously	NULL
described	NULL
,	NULL
the	NULL
frequency	NULL
of	NULL
He	NULL
``	NULL
``	NULL
was	NULL
significantly	NULL
higher	NULL
than	NULL
Val	NULL
``	NULL
°	NULL
in	NULL
atopic	NULL
asthma	NULL
patients	NULL
and	NULL
correlated	NULL
with	NULL
total	NULL
IgE	NULL
and	NULL
mite-specific	NULL
*	NULL
616	NULL
957	NULL
+99.0	NULL
1	NULL
-	NULL
/	NULL
Medium	NULL
.	NULL

|	NULL
Joo	NULL
Fresh	NULL
_	NULL
|	NULL
lf\	NULL
.	NULL

‘	NULL
\.\~/	NULL
i	NULL
a	NULL
“	NULL
£4	NULL
J	NULL
,	NULL
r/	NULL
icy	NULL
Ill	NULL
,	NULL
f	NULL
1	NULL
‘	NULL
r/	NULL
v	NULL
7	NULL
to	NULL
_/	NULL
\	NULL
'	NULL
.	NULL

’	NULL
4	NULL
w	NULL
1mm	NULL
.	NULL

\\	NULL
o	NULL
&	NULL
&	NULL
we	NULL
0	NULL
mp	NULL
|	NULL
re	NULL
rempoetemg	NULL
f	NULL
-remiig-mrran	NULL
10°	NULL
10°	NULL
10	NULL
10°	NULL
40	NULL
10°	NULL
10	NULL
10	NULL
10°	NULL
10+	NULL
Valo	NULL
?	NULL

He	NULL
?	NULL
)	NULL

B	NULL
12.5	NULL
x	NULL
10	NULL
I	NULL
LE	NULL
7.5	NULL
A	NULL
|	NULL
S	NULL
L	NULL
5	NULL
J	NULL
7	NULL
2.5	NULL
I	NULL
<	NULL
0.1	NULL
<	NULL
0.1	NULL
0	NULL
6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
IgE	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
Arg551GIn	NULL
genotype	NULL
frequency	NULL
was	NULL
invariable	NULL
in	NULL
all	NULL
three	NULL
kinds	NULL
of	NULL
classification	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
incidence	NULL
of	NULL
NeSOVal	NULL
,	NULL
but	NULL
not	NULL
Arg551GIn	NULL
,	NULL
is	NULL
correlated	NULL
with	NULL
atopic	NULL
asthma	NULL
and	NULL
that	NULL
there	NULL
is	NULL
no	NULL
linkage	NULL
disequilibrium	NULL
between	NULL
these	NULL
substitutions	NULL
.	NULL

Arg551Gln	NULL
may	NULL
be	NULL
specifically	NULL
associated	NULL
with	NULL
hyper	NULL
IgE	NULL
syndrome	NULL
and	NULL
severe	NULL
atopic	NULL
eczema	NULL
or	NULL
may	NULL
be	NULL
specific	NULL
to	NULL
Caucasians	NULL
,	NULL
although	NULL
there	NULL
has	NULL
been	NULL
a	NULL
conflicting	NULL
result	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
CD23	NULL
and	NULL
production	NULL
of	NULL
IgE	NULL
in	NULL
PBMC	NULL
genotyped	NULL
in	NULL
amino	NULL
acid	NULL
50	NULL
Our	NULL
previous	NULL
(	NULL
16	NULL
)	NULL
and	NULL
present	NULL
studies	NULL
have	NULL
verified	NULL
that	NULL
the	NULL
Ie	NULL
``	NULL
variant	NULL
amplifies	NULL
the	NULL
IL-4	NULL
signals	NULL
concerned	NULL
with	NULL
generation	NULL
of	NULL
germline	NULL
e	NULL
transcript	NULL
,	NULL
and	NULL
have	NULL
shown	NULL
high	NULL
incidence	NULL
in	NULL
patients	NULL
with	NULL
atopic	NULL
asthma	NULL
.	NULL

To	NULL
elucidate	NULL
whether	NULL
He	NULL
``	NULL
``	NULL
-bearing	NULL
PBMCs	NULL
respond	NULL
strongly	NULL
to	NULL
exogenous	NULL
hIL-4	NULL
compared	NULL
with	NULL
Val	NULL
``	NULL
-bearing	NULL
cells	NULL
,	NULL
we	NULL
assessed	NULL
expression	NULL
of	NULL
CD23	NULL
and	NULL
production	NULL
of	NULL
IgE	NULL
induced	NULL
by	NULL
IL-4	NULL
,	NULL
using	NULL
PBMCs	NULL
whose	NULL
genotypes	NULL
were	NULL
confirmed	NULL
as	NULL
homozygotes	NULL
of	NULL
either	NULL
Ile	NULL
``	NULL
or	NULL
Val	NULL
``	NULL
°	NULL
.	NULL

The	NULL
genotype	NULL
of	NULL
amino	NULL
acid	NULL
at	NULL
551	NULL
was	NULL
a	NULL
homozygote	NULL
of	NULL
Gin	NULL
in	NULL
all	NULL
of	NULL
the	NULL
investigated	NULL
donors	NULL
.	NULL

When	NULL
either	NULL
Ne	NULL
``	NULL
°-	NULL
or	NULL
Val	NULL
``	NULL
-bearing	NULL
PBMCs	NULL
from	NULL
each	NULL
of	NULL
five	NULL
donors	NULL
were	NULL
stimulated	NULL
by	NULL
hIL-4	NULL
,	NULL
CD23	NULL
expression	NULL
induced	NULL
by	NULL
hIL-4	NULL
on	NULL
CD20*	NULL
B	NULL
cells	NULL
was	NULL
slightly	NULL
higher	NULL
in	NULL
the	NULL
Ile	NULL
``	NULL
``	NULL
type	NULL
than	NULL
the	NULL
Val	NULL
``	NULL
type	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
;	NULL
the	NULL
mean	NULL
AMFI	NULL
957	NULL
vs	NULL
616	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
and	NULL
IgE	NULL
production	NULL
induced	NULL
by	NULL
hIL-4	NULL
in	NULL
the	NULL
Ile	NULL
``	NULL
``	NULL
type	NULL
was	NULL
three	NULL
times	NULL
as	NULL
high	NULL
as	NULL
the	NULL
Val	NULL
``	NULL
type	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
;	NULL
8.5	NULL
vs	NULL
2.8	NULL
ng/ml	NULL
,	NULL
respectively	NULL
)	NULL
.	NULL

These	NULL
results	NULL
were	NULL
compatible	NULL
with	NULL
our	NULL
previous	NULL
and	NULL
present	NULL
results	NULL
using	NULL
B	NULL
cell	NULL
lines	NULL
and	NULL
based	NULL
on	NULL
genetic	NULL
study	NULL
,	NULL
indicating	NULL
that	NULL
Ne	NULL
``	NULL
variant	NULL
enhanced	NULL
the	NULL
transducing	NULL
signal	NULL
for	NULL
IgE	NULL
synthesis	NULL
,	NULL
in	NULL
not	NULL
only	NULL
in	NULL
vitro	NULL
,	NULL
but	NULL
also	NULL
in	NULL
intact	NULL
B	NULL
cells	NULL
.	NULL

Further-more	NULL
,	NULL
it	NULL
would	NULL
also	NULL
be	NULL
possible	NULL
that	NULL
He	NULL
``	NULL
variant	NULL
augments	NULL
Th2	NULL
differentiation	NULL
induced	NULL
by	NULL
IL-4	NULL
,	NULL
in	NULL
synergy	NULL
with	NULL
the	NULL
variant	NULL
's	NULL
effect	NULL
on	NULL
B	NULL
cells	NULL
,	NULL
increasing	NULL
IgE	NULL
synthesis	NULL
in	NULL
PBMC	NULL
by	NULL
IL-4	NULL
.	NULL

Elucidation	NULL
of	NULL
this	NULL
point	NULL
is	NULL
awaited	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Dr.	NULL
Dovie	NULL
R.	NULL
Wylie	NULL
for	NULL
the	NULL
critical	NULL
review	NULL
of	NULL
this	NULL
manuscript	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Shirakawa	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Enomoto	NULL
,	NULL
S.	NULL
Shimazu	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Hopkin	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
inverse	NULL
association	NULL
between	NULL
tuberculin	NULL
responses	NULL
and	NULL
atopic	NULL
disorder	NULL
.	NULL

Science	NULL
275:77	NULL
.	NULL

2	NULL
.	NULL

Cookson	NULL
,	NULL
W.	NULL
O.	NULL
C.	NULL
M.	NULL
1996	NULL
.	NULL

Genetics	NULL
,	NULL
atopy	NULL
and	NULL
asthma	NULL
.	NULL

Allergology	NULL
Int	NULL
.	NULL

45:3	NULL
.	NULL

3	NULL
.	NULL

Daniels	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
S.	NULL
Bhattacharya	NULL
,	NULL
A.	NULL
James	NULL
,	NULL
N.	NULL
I	NULL
.	NULL

Leaves	NULL
,	NULL
A	NULL
.	NULL

Young	NULL
,	NULL
M.	NULL
R.	NULL
Hill	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Faux	NULL
,	NULL
G.	NULL
F.	NULL
Ryan	NULL
,	NULL
P.	NULL
N.	NULL
le	NULL
Souef	NULL
,	NULL
G.	NULL
M.	NULL
Lathrop	NULL
,	NULL
A.	NULL
W.	NULL
Musk	NULL
,	NULL
and	NULL
W.	NULL
O.	NULL
Cookson	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
genome-wide	NULL
search	NULL
for	NULL
quantitative	NULL
trait	NULL
loci	NULL
underlying	NULL
asthma	NULL
.	NULL

Nature	NULL
383:247	NULL
.	NULL

4	NULL
.	NULL

Deichmann	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
A.	NULL
Heinzmann	NULL
,	NULL
J.	NULL
Forster	NULL
,	NULL
S.	NULL
Dischinger	NULL
,	NULL
C.	NULL
Mechi	NULL
,	NULL
E.	NULL
Brueggenolte	NULL
,	NULL
F.	NULL
Hildebrandt	NULL
,	NULL
M.	NULL
Moseler	NULL
,	NULL
and	NULL
J.	NULL
Kuchr	NULL
.	NULL

1998	NULL
.	NULL

Linkage	NULL
and	NULL
allelic	NULL
association	NULL
of	NULL
atopy	NULL
and	NULL
markers	NULL
flanking	NULL
the	NULL
IL4-receptor	NULL
gene	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Allergy	NULL
28:151	NULL
.	NULL

5	NULL
.	NULL

Paul	NULL
,	NULL
W.	NULL
E.	NULL
1991	NULL
.	NULL

Interleukin-4	NULL
:	NULL
a	NULL
prototypic	NULL
immunoregulatory	NULL
lymphokine	NULL
.	NULL

Blood	NULL
77:1859	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

1231	NULL
.	NULL

Leonard	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
E.	NULL
W.	NULL
Shores	NULL
,	NULL
and	NULL
P.	NULL
E.	NULL
Love	NULL
.	NULL

1995	NULL
.	NULL

Role	NULL
of	NULL
the	NULL
common	NULL
cyto-	NULL
kine	NULL
receptor	NULL
-y	NULL
chain	NULL
in	NULL
cytokine	NULL
signaling	NULL
and	NULL
lymphoid	NULL
development	NULL
.	NULL

Immunol	NULL
.	NULL

Rev	NULL
.	NULL

148:97.	NULL
.	NULL

Harada	NULL
,	NULL
N.	NULL
,	NULL
G.	NULL
Yang	NULL
,	NULL
A.	NULL
Miyajima	NULL
,	NULL
and	NULL
M.	NULL
Howard	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
an	NULL
essential	NULL
region	NULL
for	NULL
growth	NULL
signal	NULL
transduction	NULL
in	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
of	NULL
the	NULL
human	NULL
interleukin-4	NULL
receptor	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:22752.	NULL
.	NULL

Lai	NULL
,	NULL
S.	NULL
Y.	NULL
,	NULL
J.	NULL
Molden	NULL
,	NULL
K.	NULL
D.	NULL
Liu	NULL
,	NULL
J.	NULL
M.	NULL
Puck	NULL
,	NULL
M.	NULL
D.	NULL
White	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Goldsmith	NULL
.	NULL

1996	NULL
.	NULL

Interleukin-4-specific	NULL
signal	NULL
transduction	NULL
events	NULL
are	NULL
driven	NULL
by	NULL
homotypic	NULL
interactions	NULL
of	NULL
the	NULL
interleukin-4	NULL
receptor	NULL
a	NULL
subunit	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

15:4506.	NULL
.	NULL

Kammer	NULL
,	NULL
W.	NULL
,	NULL
A.	NULL
Lischke	NULL
,	NULL
R.	NULL
Moriggl	NULL
,	NULL
B.	NULL
Groner	NULL
,	NULL
A.	NULL
Ziemiecki	NULL
,	NULL
C.	NULL
B.	NULL
Gurniak	NULL
,	NULL
L.	NULL
J.	NULL
Berg	NULL
,	NULL
and	NULL
K.	NULL
Friedrich	NULL
.	NULL

1996	NULL
.	NULL

Homodimerization	NULL
of	NULL
interleukin-4	NULL
receptor	NULL
a	NULL
chain	NULL
can	NULL
induce	NULL
intracellular	NULL
signaling	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:23634	NULL
.	NULL

Fujiwara	NULL
,	NULL
H.	NULL
,	NULL
S.	NULL
H.	NULL
Hanissian	NULL
,	NULL
A.	NULL
Tsytsykova	NULL
,	NULL
and	NULL
R.	NULL
S.	NULL
Geha	NULL
.	NULL

1997	NULL
.	NULL

Homodimerization	NULL
of	NULL
the	NULL
human	NULL
interleukin	NULL
4	NULL
receptor	NULL
«	NULL
chain	NULL
induces	NULL
Ce	NULL
germline	NULL
transcripts	NULL
in	NULL
B	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
-y	NULL
chain	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:5866	NULL
.	NULL

Reichel	NULL
,	NULL
M.	NULL
,	NULL
B.	NULL
H.	NULL
Nelson	NULL
,	NULL
P.	NULL
D.	NULL
Greenberg	NULL
,	NULL
and	NULL
P.	NULL
B.	NULL
Rothman	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
IL-4	NULL
receptor	NULL
-chain	NULL
cytoplasmic	NULL
domain	NULL
is	NULL
sufficient	NULL
for	NULL
activation	NULL
of	NULL
JAK-1	NULL
and	NULL
STAT6	NULL
and	NULL
the	NULL
induction	NULL
of	NULL
IL-4-specific	NULL
gene	NULL
expression	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158	NULL
:	NULL
5860	NULL
.	NULL

Takeda	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Tanaka	NULL
,	NULL
W.	NULL
Shi	NULL
,	NULL
M.	NULL
Matsumoto	NULL
,	NULL
M.	NULL
Minami	NULL
,	NULL
S.	NULL
Kashiwamura	NULL
,	NULL
K.	NULL
Nakanishi	NULL
,	NULL
N.	NULL
Yoshida	NULL
,	NULL
T.	NULL
Kishimoto	NULL
,	NULL
and	NULL
S.	NULL
Akira	NULL
.	NULL

1996	NULL
.	NULL

Essential	NULL
role	NULL
of	NULL
Stat6	NULL
in	NULL
IL-4	NULL
signaling	NULL
.	NULL

Nature	NULL
380:627	NULL
.	NULL

Shimoda	NULL
,	NULL
K.	NULL
,	NULL
J.	NULL
van	NULL
Deursen	NULL
,	NULL
M.	NULL
Y.	NULL
Sangster	NULL
,	NULL
S.	NULL
R.	NULL
Sarawar	NULL
,	NULL
R.	NULL
T.	NULL
Carson	NULL
,	NULL
R.	NULL
A.	NULL
Tripp	NULL
,	NULL
C.	NULL
Chu	NULL
,	NULL
F.	NULL
W.	NULL
Quelle	NULL
,	NULL
T.	NULL
Nosaka	NULL
,	NULL
D.	NULL
A	NULL
.	NULL

A.	NULL
Vignali	NULL
,	NULL
P.	NULL
C.	NULL
Doherty	NULL
,	NULL
G.	NULL
Grosveld	NULL
,	NULL
W.	NULL
E.	NULL
Paul	NULL
,	NULL
and	NULL
J.	NULL
N.	NULL
Thle	NULL
.	NULL

1996	NULL
.	NULL

Lack	NULL
of	NULL
IL-4-induced	NULL
Th2	NULL
response	NULL
and	NULL
IgE	NULL
class	NULL
switching	NULL
in	NULL
mice	NULL
with	NULL
disrupted	NULL
Stat6	NULL
gene	NULL
.	NULL

Nature	NULL
380:630	NULL
.	NULL

Kaplan	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
U.	NULL
Schindler	NULL
,	NULL
S.	NULL
T.	NULL
Smiley	NULL
,	NULL
and	NULL
M.	NULL
J.	NULL
Grusby	NULL
.	NULL

1996	NULL
.	NULL

Stat6	NULL
is	NULL
required	NULL
for	NULL
mediating	NULL
responses	NULL
to	NULL
IL-4	NULL
and	NULL
for	NULL
development	NULL
of	NULL
Th2	NULL
cells	NULL
.	NULL

Immunity	NULL
4:313	NULL
.	NULL

Mikita	NULL
,	NULL
T.	NULL
,	NULL
D.	NULL
Campbell	NULL
,	NULL
P.	NULL
Wu	NULL
,	NULL
K.	NULL
Williamson	NULL
,	NULL
and	NULL
U.	NULL
Schindler	NULL
.	NULL

1996	NULL
.	NULL

Requirements	NULL
for	NULL
interleukin-4-induced	NULL
gene	NULL
expression	NULL
and	NULL
functional	NULL
characterization	NULL
of	NULL
Stat6	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16:5811	NULL
.	NULL

Mitsuyasu	NULL
,	NULL
H.	NULL
,	NULL
K.	NULL
Izubara	NULL
,	NULL
X.-Q	NULL
.	NULL

Mao	NULL
,	NULL
P.-S.	NULL
Gao	NULL
,	NULL
Y.	NULL
Arinobu	NULL
,	NULL
T.	NULL
Enomoto	NULL
,	NULL
M.	NULL
Kawai	NULL
,	NULL
S.	NULL
Sasaki	NULL
,	NULL
Y.	NULL
Dake	NULL
,	NULL
N.	NULL
Hamasaki	NULL
,	NULL
T.	NULL
Shirakawa	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Hopkin	NULL
.	NULL

1998	NULL
.	NULL

IleSOVal	NULL
variant	NULL
of	NULL
IL4Ra	NULL
upregulates	NULL
IgE	NULL
synthesis	NULL
and	NULL
associates	NULL
with	NULL
atopic	NULL
asthma	NULL
.	NULL

Nat	NULL
.	NULL

Genet	NULL
.	NULL

19:119	NULL
.	NULL

Khurana	NULL
Hershey	NULL
,	NULL
G.	NULL
K.	NULL
,	NULL
M.	NULL
F.	NULL
Friedrich	NULL
,	NULL
L.	NULL
A.	NULL
Esswein	NULL
,	NULL
M.	NULL
L.	NULL
Thomas	NULL
,	NULL
and	NULL
T.	NULL
A.	NULL
Chatila	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
association	NULL
of	NULL
atopy	NULL
with	NULL
a	NULL
gain-of-function	NULL
mutation	NULL
in	NULL
the	NULL
a	NULL
subunit	NULL
of	NULL
the	NULL
interleukin-4	NULL
receptor	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

337:1720	NULL
.	NULL

Kunkel	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

1985	NULL
.	NULL

Rapid	NULL
and	NULL
efficient	NULL
site-specific	NULL
mutagenesis	NULL
without	NULL
phe-notypic	NULL
selection	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
82:488	NULL
.	NULL

Izubara	NULL
,	NULL
K.	NULL
,	NULL
T.	NULL
Heike	NULL
,	NULL
T.	NULL
Otsuka	NULL
,	NULL
K.	NULL
Yamaoka	NULL
,	NULL
M.	NULL
Mayumi	NULL
,	NULL
T.	NULL
Imamura	NULL
,	NULL
Y.	NULL
Niho	NULL
,	NULL
and	NULL
N.	NULL
Harada	NULL
.	NULL

1996	NULL
.	NULL

Signal	NULL
transduction	NULL
pathway	NULL
of	NULL
Interleukin-4	NULL
and	NULL
Interleukin-13	NULL
in	NULL
human	NULL
B	NULL
cells	NULL
derived	NULL
from	NULL
X-linked	NULL
severe	NULL
combined	NULL
immu-nodeficiency	NULL
patients	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:619	NULL
.	NULL

Izubara	NULL
,	NULL
K.	NULL
,	NULL
A.	NULL
Miyajima	NULL
,	NULL
and	NULL
N.	NULL
Harada	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
chimeric	NULL
receptor	NULL
between	NULL
interleukin-2	NULL
receptor	NULL
B	NULL
chain	NULL
and	NULL
interleukin-4	NULL
receptor	NULL
transduces	NULL
interleukin-2	NULL
signal	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

190:992	NULL
.	NULL

Izubara	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
N.	NULL
Harada	NULL
.	NULL

1993	NULL
.	NULL

Interleukin-4	NULL
(	NULL
IL-4	NULL
)	NULL
induces	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
the	NULL
IL-4	NULL
receptor	NULL
and	NULL
association	NULL
of	NULL
phosphatidylinositol	NULL
3-ki-nase	NULL
to	NULL
the	NULL
IL-4	NULL
receptor	NULL
in	NULL
a	NULL
mouse	NULL
T	NULL
cell	NULL
line	NULL
,	NULL
HT2	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:13097	NULL
.	NULL

Mao	NULL
,	NULL
X.	NULL
Q.	NULL
,	NULL
T.	NULL
Shirakawa	NULL
,	NULL
K.	NULL
Yoshikawa	NULL
,	NULL
M.	NULL
Kawai	NULL
,	NULL
S.	NULL
Sasaki	NULL
,	NULL
T.	NULL
Enomoto	NULL
,	NULL
T.	NULL
Hashimoto	NULL
,	NULL
J.	NULL
Furuyama	NULL
,	NULL
J.	NULL
M.	NULL
Hopkin	NULL
,	NULL
and	NULL
K.	NULL
Morimoto	NULL
.	NULL

1996	NULL
.	NULL

Association	NULL
between	NULL
genetic	NULL
variants	NULL
of	NULL
mast-cell	NULL
chymase	NULL
and	NULL
eczema	NULL
.	NULL

Lancet	NULL
348:581	NULL
.	NULL

Yanagihara	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Kiniwa	NULL
,	NULL
K.	NULL
Kajiwara	NULL
,	NULL
and	NULL
T.	NULL
Shida	NULL
.	NULL

1992	NULL
.	NULL

Establishment	NULL
of	NULL
a	NULL
sensitive	NULL
radioimmunoassay	NULL
for	NULL
the	NULL
detection	NULL
of	NULL
human	NULL
IgE-binding	NULL
factor	NULL
(	NULL
sol-uble	NULL
CD23	NULL
)	NULL
.	NULL

Int	NULL
.	NULL

Arch	NULL
.	NULL

Allergy	NULL
Immunol	NULL
.	NULL

98:189	NULL
.	NULL

Yanagihara	NULL
,	NULL
Y.	NULL
,	NULL
K.	NULL
Kajiwara	NULL
,	NULL
M.	NULL
Kiniwa	NULL
,	NULL
Y.	NULL
Yui	NULL
,	NULL
T.	NULL
Shida	NULL
,	NULL
and	NULL
G.	NULL
Delespesse	NULL
.	NULL

1987	NULL
.	NULL

Enhancement	NULL
of	NULL
IgB	NULL
synthesis	NULL
and	NULL
histamine	NULL
release	NULL
by	NULL
T	NULL
cell	NULL
factors	NULL
derived	NULL
from	NULL
atopic	NULL
patients	NULL
with	NULL
bronchial	NULL
asthma	NULL
.	NULL

J	NULL
.	NULL

Allergy	NULL
Clin	NULL
.	NULL

Immunol	NULL
.	NULL

79:448	NULL
.	NULL

Schulte	NULL
,	NULL
T.	NULL
,	NULL
R.	NULL
Kurrle	NULL
,	NULL
M.	NULL
Réllinghoff	NULL
,	NULL
and	NULL
A.	NULL
Gessner	NULL
.	NULL

1997	NULL
.	NULL

Molecular	NULL
characterization	NULL
and	NULL
functional	NULL
analysis	NULL
of	NULL
murine	NULL
interleukin	NULL
4	NULL
receptor	NULL
allotypes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

186:1419	NULL
.	NULL

Grimbacher	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
S.	NULL
M.	NULL
Holland	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
interleukin-4	NULL
receptor	NULL
variant	NULL
Q576R	NULL
in	NULL
hyper-IgB	NULL
syndrome	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

338:1073	NULL
.	NULL

6107	NULL
'01	NULL
4epy	NULL
uo	NULL
1san8	NULL
4q	NULL
jountwrut	NULL
{	NULL
'mmmy	NULL
;	NULL
/	NULL
:	NULL
dyy	NULL
wor	NULL
;	NULL

